Corthera raises $23 million

Corthera (San Mateo, Calif.) raised $23 million in a series C round. New investor Caxton Advantage Life Sciences Fund joined existing investors Domain Associates and Kleiner, Perkins, Caufield & Byers for the round. The company's Relaxin, a naturally occurring peptide hormone, has completed Phase Ia testing to treat acute heart failure. Corthera has rights to Relaxin from Connetics, a subsidiary of Stiefel (Coral Gables, Fla.). ...